Watch TVRD. Know when insiders buy.
One email the day a filing lands. Free.
TVRD
Tvardi Therapeutics, Inc.
1.24
−0.01 −0.80%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $16.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$26.1MNET CASH —52W 1.06 – 42.98SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$6.6M | −$6.5M | −255.0% | -0.69 | −$9.2M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$7.1M | −$6.8M | — | -0.73 | −$5.9M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$7.6M | −$7.3M | — | -0.76 | −$5.7M | — | — | Aug 14 |
| Q3 2025 · Sep 30 | — | — | — | −$5.9M | −$5.5M | — | -0.59 | −$4.3M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$8.9M | $4.2M | — | -1.00 | −$5.9M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $2.6M | +20.3% | — | −$4.4M | −$9.6M | — | -3.72 | −$7.7M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | $1.5M | −51.6% | — | −$10.8M | −$12.7M | — | -4.94 | −$4.8M | $0 | −$4.8M | Mar 31 |
| Q3 2024 · Sep 30 | $2.6M | −47.5% | — | −$5.7M | −$5.5M | — | -2.14 | −$6.7M | $0 | −$6.7M | Nov 13 |
| Q2 2024 · Jun 30 | $991K | — | — | −$7.2M | −$7M | — | -2.71 | $23.6M | $210K | $23.4M | Nov 13 |
| Q1 2024 · Mar 31 | $2.1M | — | — | −$29.7M | −$4.2M | — | -20.24 | −$30.5M | $836K | −$31.3M | Nov 13 |
| Q4 2023 · Dec 31derived | $3M | — | — | −$32.6M | −$32.3M | — | -24.67 | −$17.4M | $2.1M | −$19.4M | Mar 11 |
| Q3 2023 · Sep 30 | $4.9M | — | — | −$28.9M | −$28M | — | -0.52 | −$19.6M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$26.7M | −$18.2M | — | -3.26 | −$23.5M | — | — | — | — |
| FY2024 · to Dec 31 | $7.1M | — | −$28.1M | −$29.4M | -411.9% | -11.42 | −$18.3M | $1M | −$19.4M | — | — |
| FY2023 · to Dec 31 | $21M | — | −$121.5M | −$118.5M | -565.2% | -26.26 | −$92.1M | $2.4M | −$94.5M | — | — |
| FY2022 · to Dec 31 | $41.9M | — | −$87.5M | −$85.5M | -204.2% | -19.12 | −$78.7M | $43K | −$78.8M | — | — |
| FY2021 · to Dec 31 | $23M | 100.0% | −$89.1M | −$88.4M | -384.1% | -1.74 | −$60.1M | $39K | −$60.1M | — | — |
| FY2020 · to Dec 31 | $135.1M | — | $5.4M | $8.4M | 6.2% | 0.18 | −$5.5M | $349K | −$5.8M | — | — |
Every number comes from Tvardi Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.